Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 14;120(3):217-219.
doi: 10.1093/cvr/cvae033.

The dual effects of miR-222 in cardiac hypertrophy: bridging pathological and physiological paradigms

Despoina Kesidou  1 , Abdelaziz Beqqali  1 , Andrew H Baker  1   2
Affiliations
Editorial

The dual effects of miR-222 in cardiac hypertrophy: bridging pathological and physiological paradigms

Despoina Kesidou et al. Cardiovasc Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none declared.

Figures

Figure 1
Figure 1
The dual effects of miR-222 under exercise- and pressure overload-induced hypertrophy. miRNA-222 is upregulated in physiological cardiac-induced hypertrophy following exercise and pathological cardiac-induced hypertrophy following TAC. Under physiological hypertrophy, miRNA inhibition blocks cardiac and cardiomyocyte growth, suggesting a role in physiological cardiac growth. Following TAC, miRNA inhibition accelerates pathological hypertrophy, cardiac dysfunction, and heart failure, while miRNA cardiac-specific expression attenuates pathological hypertrophy, cardiac function, and survival suggesting a role in the inhibition of pathological cardiac growth. The figure represents validated targets of miR-222 in each scenario. The figure was created with BioRender.com.
See this image and copyright information in PMC

Comment on

References

    1. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 2018;15:387–407. - PubMed
    1. Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol 2023;20:347–363. - PMC - PubMed
    1. Kansakar U, Varzideh F, Mone P, Jankauskas SS, Santulli G. Functional role of microRNAs in regulating cardiomyocyte death. Cells 2022;11:983. - PMC - PubMed
    1. Braga L, Ali H, Secco I, Giacca M. Non-coding RNA therapeutics for cardiac regeneration. Cardiovasc Res 2021;117:674–693. - PMC - PubMed
    1. Kesidou D, da Costa Martins PA, de Windt LJ, Brittan M, Beqqali A, Baker AH. Extracellular vesicle miRNAs in the promotion of cardiac neovascularisation. Front Physiol 2020;11:579892. - PMC - PubMed